Ana Cecília Bezerra Carvalho1, Túlio Nader Lana2, João Paulo Silvério Perfeito3, Dâmaris Silveira4. 1. Gerência Geral de Medicamentos. Agência Nacional de Vigilância Sanitária (Anvisa), SIA, Trecho 5, Área Especial 57, Brasília 71205-050, DF, Brazil. Electronic address: anacecijp@yahoo.com.br. 2. Gerência Geral de Medicamentos. Agência Nacional de Vigilância Sanitária (Anvisa), SIA, Trecho 5, Área Especial 57, Brasília 71205-050, DF, Brazil. Electronic address: naderlanatulio@gmail.com. 3. Gerência Geral de Medicamentos. Agência Nacional de Vigilância Sanitária (Anvisa), SIA, Trecho 5, Área Especial 57, Brasília 71205-050, DF, Brazil. Electronic address: jpperfeito@gmail.com. 4. Laboratório de Controle da Qualidade, Faculdade de Ciências da Saúde, Universidade de Brasília (UnB). Campus Universitário Darcy Ribeiro, Asa Norte, Brasília 70810-900, DF, Brazil. Electronic address: damaris1803@yahoo.com.br.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: the herbal medicinal products (HMP) market is expanding in the world, an expansion that has not occurred in Brazil when considering the number of licensed products. Despite being a megadiverse country, the number of HMP licensed in Brazil is small, and the number of HMP obtained from native species is even smaller. A new legislation for herbal products licensing, which divides the products into two categories, Herbal Medicine (HM) and Traditional Herbal Product (THP) was launched in Brazil focusing on traditional use, as well as a law regulating the use of biodiversity and traditional knowledge. AIM OF THE STUDY: to evaluate the situation of HMP licensed in Brazil and to make a comparison with the data obtained in 2008 and 2011, discussing the evolution of the licensed products and the possible impacts of the new legislation. MATERIALS AND METHODS: a survey was carried out in the Brazilian Health Regulatory Agency (Anvisa) database to verify the HMP licensed in Brazil in September 2016. The data obtained were compared with two surveys previously published. RESULTS: There are 332 single, and 27 combined HM, totaling 359 HM licensed in Brazil. There is no THP notified in Anvisa's system yet. There are 214 HM classified as nonprescription (OTC), while 145 are sold under prescription, one of them with prescription retention. There are 101 plant species licensed as active in HM in Brazil, 39 of which are native, adapted or cultivated. The most licensed plant species is Mikania glomerata Spreng., with 25 HM licensed. The article includes tables with plant species that have derivatives licensed as simple and combined HM, their therapeutic classification, the native plant species indication and the distribution of the companies by Brazilian regions. CONCLUSIONS: There are few licensed HM in Brazil, and this number has been decreasing in recent years. It is expected that the data obtained, together with the changes promoted in sanitary and environmental rules, will help to develop and regulate HMP chain in Brazil.
ETHNOPHARMACOLOGICAL RELEVANCE: the herbal medicinal products (HMP) market is expanding in the world, an expansion that has not occurred in Brazil when considering the number of licensed products. Despite being a megadiverse country, the number of HMP licensed in Brazil is small, and the number of HMP obtained from native species is even smaller. A new legislation for herbal products licensing, which divides the products into two categories, Herbal Medicine (HM) and Traditional Herbal Product (THP) was launched in Brazil focusing on traditional use, as well as a law regulating the use of biodiversity and traditional knowledge. AIM OF THE STUDY: to evaluate the situation of HMP licensed in Brazil and to make a comparison with the data obtained in 2008 and 2011, discussing the evolution of the licensed products and the possible impacts of the new legislation. MATERIALS AND METHODS: a survey was carried out in the Brazilian Health Regulatory Agency (Anvisa) database to verify the HMP licensed in Brazil in September 2016. The data obtained were compared with two surveys previously published. RESULTS: There are 332 single, and 27 combined HM, totaling 359 HM licensed in Brazil. There is no THP notified in Anvisa's system yet. There are 214 HM classified as nonprescription (OTC), while 145 are sold under prescription, one of them with prescription retention. There are 101 plant species licensed as active in HM in Brazil, 39 of which are native, adapted or cultivated. The most licensed plant species is Mikania glomerata Spreng., with 25 HM licensed. The article includes tables with plant species that have derivatives licensed as simple and combined HM, their therapeutic classification, the native plant species indication and the distribution of the companies by Brazilian regions. CONCLUSIONS: There are few licensed HM in Brazil, and this number has been decreasing in recent years. It is expected that the data obtained, together with the changes promoted in sanitary and environmental rules, will help to develop and regulate HMP chain in Brazil.
Authors: Adrieli Rodrigues da Costa Nunes; Claudete Aparecida Mangolin; Arildo José Braz de Oliveira; Regina Aparecida Correia Gonçalves; Alexandre da Silva Avincola; Rafaela Takako Ribeiro de Almeida; Eduardo Jorge Pilau; Maria de Fátima Pires da Silva Machado Journal: Curr Res Food Sci Date: 2022-06-09
Authors: Tatiane R Amparo; Janaína B Seibert; Tamires C Almeida; Fernanda S F Costa; Benila M Silveira; Glenda N da Silva; Orlando D H Dos Santos; Gustavo H B de Souza Journal: Phytother Res Date: 2021-04-01 Impact factor: 6.388
Authors: Rafael M Palhares; Leopoldo C Baratto; Marina Scopel; Fernanda L B Mügge; Maria G L Brandão Journal: Front Pharmacol Date: 2021-01-27 Impact factor: 5.810